ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) and Lyra Therapeutics (OTCMKTS:LYRA – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Valuation & Earnings
This table compares ARS Pharmaceuticals and Lyra Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ARS Pharmaceuticals | $84.28 million | 5.09 | -$171.30 million | ($2.18) | -1.98 |
| Lyra Therapeutics | $400,000.00 | 0.13 | -$28.92 million | ($19.15) | -0.00 |
Profitability
This table compares ARS Pharmaceuticals and Lyra Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ARS Pharmaceuticals | -184.24% | -256.67% | -69.63% |
| Lyra Therapeutics | -7,266.08% | N/A | -59.82% |
Insider & Institutional Ownership
68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Ratings
This is a breakdown of current ratings for ARS Pharmaceuticals and Lyra Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ARS Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Lyra Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
ARS Pharmaceuticals currently has a consensus price target of $25.00, suggesting a potential upside of 480.05%. Given ARS Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than Lyra Therapeutics.
Volatility & Risk
ARS Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Lyra Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.
Summary
ARS Pharmaceuticals beats Lyra Therapeutics on 9 of the 14 factors compared between the two stocks.
About ARS Pharmaceuticals
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
About Lyra Therapeutics
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
